Abstract
The beneficial effects of chronic exercise training on lipoprotein metabolism include a considerable increase in serum high density lipoprotein-cholesterol and a reduction in serum triglyceride levels. These changes are mostly reported in athletes participating in dynamic sports, especially in the endurance ones. Diagnosis and treatment of dyslipidaemias in athletes should follow the main principles of management of dyslipidaemias for the general population, while specific considerations for athletes should be taken into account. Dyslipidaemias in athletes are usually characterized by a significant genetic predisposition. Clinicians who evaluate the lipoprotein profile of athletes should keep in mind the possibility of an illegal use of performance-enhancing drugs, which can influence lipoprotein metabolism. Lifestyle intervention should be the cornerstone of treatment of dyslipidaemias in athletes, but it should be tailored to the needs of individual athletic activity. Hypolipidaemic medications may not be well-tolerated by competitive athletes and should be reserved only for athletes with inadequate response to lifestyle measures. The treatment of dyslipidaemias in athletes should aim at reducing cardiovascular risk without compromising athletic performance.
Keywords: Sports, dyslipidaemia, athletes, lipoproteins, high density lipoprotein-cholesterol, triglycerides.
Current Vascular Pharmacology
Title:Diagnosis and Treatment of Dyslipidaemias in Athletes
Volume: 15 Issue: 3
Author(s): Georgios A. Christou, Evangelia J. Kouidi, Asterios P. Deligiannis and Dimitrios N. Kiortsis*
Affiliation:
- Laboratory of Physiology, Medical School, University of Ioannina, 45110 Ioannina,Greece
Keywords: Sports, dyslipidaemia, athletes, lipoproteins, high density lipoprotein-cholesterol, triglycerides.
Abstract: The beneficial effects of chronic exercise training on lipoprotein metabolism include a considerable increase in serum high density lipoprotein-cholesterol and a reduction in serum triglyceride levels. These changes are mostly reported in athletes participating in dynamic sports, especially in the endurance ones. Diagnosis and treatment of dyslipidaemias in athletes should follow the main principles of management of dyslipidaemias for the general population, while specific considerations for athletes should be taken into account. Dyslipidaemias in athletes are usually characterized by a significant genetic predisposition. Clinicians who evaluate the lipoprotein profile of athletes should keep in mind the possibility of an illegal use of performance-enhancing drugs, which can influence lipoprotein metabolism. Lifestyle intervention should be the cornerstone of treatment of dyslipidaemias in athletes, but it should be tailored to the needs of individual athletic activity. Hypolipidaemic medications may not be well-tolerated by competitive athletes and should be reserved only for athletes with inadequate response to lifestyle measures. The treatment of dyslipidaemias in athletes should aim at reducing cardiovascular risk without compromising athletic performance.
Export Options
About this article
Cite this article as:
Christou A. Georgios, Kouidi J. Evangelia, Deligiannis P. Asterios and Kiortsis N. Dimitrios*, Diagnosis and Treatment of Dyslipidaemias in Athletes, Current Vascular Pharmacology 2017; 15 (3) . https://dx.doi.org/10.2174/1570161115666170127162526
DOI https://dx.doi.org/10.2174/1570161115666170127162526 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Advancements in Arterial Stiffness: Novel Therapeutic Frontiers
Arterial stiffness, a hallmark of cardiovascular disease, poses significant challenges in contemporary healthcare. This thematic issue delves into the multifaceted landscape of arterial stiffness and explores cutting-edge therapeutic interventions aimed at mitigating its adverse effects. Within these pages, readers will find a comprehensive overview of the mechanisms underlying arterial stiffness, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Acute Coronary Syndromes in Patients with Atrial Fibrillation and Heart Failure. Could Novel Oral Anticoagulants be the Solution of the Optimal Antithrombotic Therapy Puzzle?
Cardiovascular & Hematological Agents in Medicinal Chemistry Acute Decompensated Heart Failure Update
Current Cardiology Reviews Therapeutic Advances in the Treatment of Alzheimer's Disease: Present and Future
Current Drug Therapy Astrocytes: Targets for Neuroprotection in Stroke
Central Nervous System Agents in Medicinal Chemistry Management of Incidental Findings in the Era of Next-generation Sequencing
Current Genomics Anticancer Potential of Mefenamic Acid Derivatives with Platelet-Derived Growth Factor Inhibitory Property
Anti-Cancer Agents in Medicinal Chemistry Emerging Protein Biomarkers in Epithelial Ovarian Cancer Prognosis: An Aid for Multivariate Indexing
Current Protein & Peptide Science Tissue Engineering Applications and Stem Cell Approaches to the Skin, Nerves and Blood Vessels
Current Stem Cell Research & Therapy Modifiable Risk Factors for Dementia: The Role of Gut Microbiota
Current Alzheimer Research Regeneration in a Degenerating Brain: Potential of Allopregnanolone as a Neuroregenerative Agent
Current Alzheimer Research MicroRNA-16-5p Aggravates Myocardial Infarction Injury by Targeting the Expression of Insulin Receptor Substrates 1 and Mediating Myocardial Apoptosis and Angiogenesis
Current Neurovascular Research The Importance of Reendothelialization After Arterial Injury
Current Pharmaceutical Design Compared Chemical Activity and Effects on Cell Viability of Various Antioxidant Compounds
Current Analytical Chemistry Angiogenesis Inhibition: State of the Art, Forgotten Strategies and New Perspectives in Cancer Therapy
Current Cancer Therapy Reviews Omega-3 and Renal Function in Older Adults
Current Pharmaceutical Design Responses Triggered by the Immune System in Hypertensive Conditions and Repercussions on Target Organ Damage: A Review
Current Cardiology Reviews Mesenchymal Stem Cell Therapy in Intracerebral Haemorrhagic Stroke
Current Medicinal Chemistry Inhibitors of the Proteolytic Activity of Urokinase Type Plasminogen Activator
Current Pharmaceutical Design Reduction of eNOS in Vascular Smooth Muscle by Salt Independently of Hypertension
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Is HIV Involved in the Pathogenesis of Non-Infectious Pulmonary Complications in Infected Patients?
Current HIV Research